In patients with T2DM with underlying ischemic heart disease who were receiving metformin and insulin therapy, endothelial function in the group of patients with T2DM with an HbA1c > 7.0% at baseline was improved by additional therapy with dapagliflozin for 12 weeks compared to placebo [34]. Here, INS is linked to coronary artery disorder.